前收市價 | 417.32 |
開市 | 419.48 |
買盤 | 418.04 x 100 |
賣出價 | 418.55 x 100 |
今日波幅 | 415.06 - 420.67 |
52 週波幅 | 310.90 - 448.40 |
成交量 | |
平均成交量 | 1,315,203 |
市值 | 107.975B |
Beta 值 (5 年,每月) | 0.35 |
市盈率 (最近 12 個月) | 30.07 |
每股盈利 (最近 12 個月) | 13.90 |
業績公佈日 | 2024年4月29日 - 2024年5月03日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 464.98 |
Crispr stock is down for the fifth straight week as the top Cathie Wood's holding struggles amid dim expectations for its gene-editing drug.
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $416.03, indicating a +0.09% shift from the previous trading day.
While CF remains the main area of focus for Vertex Pharmaceuticals (VRTX), it is seeing success in the development of its non-CF pipeline candidates.